Business Wire

DE-ROCKET.CHAT

22.7.2021 14:02:09 CEST | Business Wire | Press release

Share
Rocket.Chat Announces Partner Program Upgrade To Expand Ecosystem and Consolidate Its Presence Across the Globe

Rocket.Chat , the leading open-source communication hub, is announcing the release of Catalyst , its new partner program that consolidates all the assets needed to accelerate growth of new and existing partners across the globe.

“Since the beginning we have been working in close collaboration with service and technology providers to deliver increased value to our customers, which naturally led us to clearly understand the key aspects needed to support our partners’ growth throughout their journey and ultimately leverage their ROI through our partnership. Rocket.Chat’s Catalyst materializes these learnings into a journey-based program that will support companies of all sizes that target the same market and want to establish a results-driven, long-lasting relationship with Rocket.Chat,” said Julio Azzini, Global Head of Partnerships at Rocket.Chat.

The pandemic forced businesses around the globe to abruptly adopt the remote work environment, on a never-before-seen scale. This presented a unique opportunity for Rocket.Chat, helping to boost the company’s hyper growth - a trend that is set to continue as evidence mounts that the remote work momentum will not fade away for the foreseeable future. As an open-source business, Rocket.Chat benefits from a strong global footprint across different sectors that, combined with its recent Series A funding round , will accelerate growth and create opportunities for both Rocket.Chat and its partner ecosystem.

“The investment we made to revamp our existing (partner) program reinforces our commitment to our partners and ultimately, to our customers, to better serve them at a local level and on a global scale. Our partner ecosystem plays a crucial role in our go-to-market strategy,” shared Gabriel Engel, co-founder and CEO of Rocket.Chat. “Partners act as our service arm because they are the ones who are implementing strategic projects, scaling our apps and setting up the integrations that enable our customers to personalize and make the most of their Rocket.Chat experience.”

The new program encompasses a self-paced, scalable onboarding process that enables all key roles within a partner organization to sell and deliver projects through the Rocket.Chat partner portal. The robust capabilities of the program increase collaboration between internal teams and external providers to better manage the partner experience and overall journey while working within Rocket.Chat.

“We decided to implement the same training that we provide to our internal team to our partners. We see our partner relationships as a critical part of our company, rather than just a go-to-market channel. On top of all improvements made we have hired a very talented and competent group of professionals, now outfitted with the assets they need to ensure that we are taking our partner program -- and ultimately our partnerships -- to the next level,” added Azzini.

The new partner program operates across three tiers that are organized based on the overall capabilities and contributions of partners across all types of business models. For more information, please visit: www.Rocket.Chat/partners

About Rocket.Chat

Rocket.Chat is used by Audi, Alfa-Bank, Caixa, Daimler, HTC, Intel, Lockheed Martin, Nationwide Insurance, and other enterprises worldwide to control their communication, manage their data, and have their own collaboration platform to improve team productivity. Rocket.Chat users can switch between team chat and video or audio calls with screen sharing for more efficient teamwork. The platform’s open-source foundation empowers enterprises with complete access to the source code so that they can fully customize, extend or add new functionality to meet their unique requirements. Rocket.Chat is now installed on more than 700,000 servers, counts over 12 million users worldwide, and has an active, passionate community of over 800 developer-contributors who help Rocket.Chat’s core team of developers to constantly improve the product.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study23.10.2026 13:30:00 CEST | Press release

Data from the Registrational Phase 3 G-HOPE-001 Study of Arcotatug Tavatecan, a Novel, Potential Best-in-Class Claudin (CLDN)18.2 ADC, were Highlighted in a Late-Breaking Presentation at ESMO 2026Arcotatug Tavatecan Met Dual Primary Endpoints of Overall Survival and Progression-Free Survival, Showing Significant Improvements vs. Treatment of Physician’s Choice in Patients with Previously Treated CLDN18.2-Positive Advanced Gastric CancerFindings to Support Planned Regulatory Filing in Japan and Continued Global Development of Arcotatug Tavatecan in CLDN18.2-Positive Cancers Takeda(TSE:4502/NYSE:TAK)announced positive results from the Phase 3 G-HOPE-001 study (NCT06238843) of arcotatug tavatecan (TAK-921; Innovent R&D code: IBI343) in patients with Claudin (CLDN)18.2-positive, previously treated, advanced gastric or gastroesophageal junction adenocarcinoma (G/GEJA). Results from two prespecified interim analyses, which were shared in a late-breaking oral presentation at the 2026 European

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye